123 related articles for article (PubMed ID: 38720417)
1. Efficacy and safety of inactivated SARS-CoV-2 vaccination in COVID-19-associated pneumonia among patients with rheumatic and musculoskeletal diseases: A real-world retrospective observational study.
Liu S; Jin Z; Feng X; Da Z; Tang Y; Hu H; Wang D; Sun L
Int J Rheum Dis; 2024 May; 27(5):e15166. PubMed ID: 38720417
[TBL] [Abstract][Full Text] [Related]
2. Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry.
Machado PM; Lawson-Tovey S; Strangfeld A; Mateus EF; Hyrich KL; Gossec L; Carmona L; Rodrigues A; Raffeiner B; Duarte C; Hachulla E; Veillard E; Strakova E; Burmester GR; Yardımcı GK; Gomez-Puerta JA; Zepa J; Kearsley-Fleet L; Trefond L; Cunha M; Mosca M; Cornalba M; Soubrier M; Roux N; Brocq O; Durez P; Conway R; Goulenok T; Bijlsma JW; McInnes IB; Mariette X
Ann Rheum Dis; 2022 May; 81(5):695-709. PubMed ID: 34972811
[TBL] [Abstract][Full Text] [Related]
3. Low frequency of disease flare in patients with rheumatic musculoskeletal diseases who received SARS-CoV-2 mRNA vaccine.
Spinelli FR; Favalli EG; Garufi C; Cornalba M; Colafrancesco S; Conti F; Caporali R
Arthritis Res Ther; 2022 Jan; 24(1):21. PubMed ID: 35016701
[TBL] [Abstract][Full Text] [Related]
4. Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations.
Kroon FPB; Najm A; Alunno A; Schoones JW; Landewé RBM; Machado PM; Navarro-Compán V
Ann Rheum Dis; 2022 Mar; 81(3):422-432. PubMed ID: 34876462
[TBL] [Abstract][Full Text] [Related]
5. Clinical features of patients with rheumatic and musculoskeletal diseases during the coronavirus disease 2019 pandemic and the association of its relapse with infection: Across-sectional study.
Zhang Y; Xu P; Huang J; Hu Z
Int J Rheum Dis; 2024 Apr; 27(4):e15150. PubMed ID: 38661306
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of booster vaccination with inactivated COVID-19 vaccines against SARS-CoV-2 Omicron BA.2 infection in Guangdong, China: a cohort study.
He X; Zeng B; Wang Y; Pang Y; Zhang M; Hu T; Liang Y; Kang M; Tang S
Front Immunol; 2023; 14():1257360. PubMed ID: 37915583
[TBL] [Abstract][Full Text] [Related]
7. Safety of the ChAdOx1 nCoV-19 and the BBV152 vaccines in 724 patients with rheumatic diseases: a post-vaccination cross-sectional survey.
Cherian S; Paul A; Ahmed S; Alias B; Manoj M; Santhosh AK; Varghese DR; Krishnan N; Shenoy P
Rheumatol Int; 2021 Aug; 41(8):1441-1445. PubMed ID: 34142203
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of inactivated COVID-19 vaccination in adult rheumatic patients in South China: a prospective study.
Zeng H; Liu H; Liu Z; Zhou X; Lu X; Yan Z; Zhou Y; Dai L; Chen Y; Yang T; Yin Z; Ye Z
Hum Vaccin Immunother; 2022 Nov; 18(5):2090176. PubMed ID: 35878733
[TBL] [Abstract][Full Text] [Related]
9. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F
Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362
[TBL] [Abstract][Full Text] [Related]
10. SARS-COV-2 vaccine acceptance in patients with rheumatic diseases: a cross-sectional study.
Ko T; Dendle C; Woolley I; Morand E; Antony A
Hum Vaccin Immunother; 2021 Nov; 17(11):4048-4056. PubMed ID: 34357827
[TBL] [Abstract][Full Text] [Related]
11. An Argentinean cohort of patients with rheumatic and immune-mediated diseases vaccinated for SARS-CoV-2: the SAR-CoVAC Registry-protocol and preliminary data.
Isnardi CA; Schneeberger EE; Kreimer JL; Luna PC; Echeverría C; Roberts K; de la Vega MC; Virasoro BM; Landi M; Quintana R; Exeni MED; Kogan N; Petkovic I; Pereira D; De Los Ángeles Correa M; Zelaya MD; Tissera Y; Elkin MSG; Pisoni CN; Alonso C; Cogo AK; Cosatti MA; García L; Retamozo C; de Los Ángeles Severina M; Nieto RE; Rosemffet M; Mussano E; Bertoli A; Savio VG; Cosentino V; Pons-Estel GJ
Clin Rheumatol; 2022 Oct; 41(10):3199-3209. PubMed ID: 35760939
[TBL] [Abstract][Full Text] [Related]
12. Disease Flare and Reactogenicity in Patients With Rheumatic and Musculoskeletal Diseases Following Two-Dose SARS-CoV-2 Messenger RNA Vaccination.
Connolly CM; Ruddy JA; Boyarsky BJ; Barbur I; Werbel WA; Geetha D; Garonzik-Wang JM; Segev DL; Christopher-Stine L; Paik JJ
Arthritis Rheumatol; 2022 Jan; 74(1):28-32. PubMed ID: 34346185
[TBL] [Abstract][Full Text] [Related]
13. Humoral and Cellular Immunogenicity and Safety of Five Different SARS-CoV-2 Vaccines in Patients With Autoimmune Rheumatic and Musculoskeletal Diseases in Remission or With Low Disease Activity and in Healthy Controls: A Single Center Study.
Szebeni GJ; Gémes N; Honfi D; Szabó E; Neuperger P; Balog JÁ; Nagy LI; Szekanecz Z; Puskás LG; Toldi G; Balog A
Front Immunol; 2022; 13():846248. PubMed ID: 35432314
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
15. Dynamics of SARS-CoV-2 IgG antibodies and neutralising antibodies in rheumatic and musculoskeletal diseases patients with COVID-19.
Wang Q; Wu Y; Wu L; Lu C; Ke Y; Wang Y; Gu L; Shen Y; Tan W
Clin Exp Rheumatol; 2024 May; 42(5):1035-1042. PubMed ID: 38372719
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 vaccine safety in adolescents with inflammatory rheumatic and musculoskeletal diseases and adults with juvenile idiopathic arthritis: data from the EULAR COVAX physician-reported registry.
Lawson-Tovey S; Machado PM; Strangfeld A; Mateus E; Gossec L; Carmona L; Raffeiner B; Bulina I; Clemente D; Zepa J; Rodrigues AM; Mariette X; Hyrich KL;
RMD Open; 2022 Jul; 8(2):. PubMed ID: 35908834
[TBL] [Abstract][Full Text] [Related]
17. Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe?
Santos CS; Férnandez XC; Moriano Morales C; Álvarez ED; Álvarez Castro C; López Robles A; Pérez Sandoval T
RMD Open; 2021 Jan; 7(1):. PubMed ID: 33455920
[TBL] [Abstract][Full Text] [Related]
18. Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases.
Hasseli R; Mueller-Ladner U; Hoyer BF; Krause A; Lorenz HM; Pfeil A; Richter J; Schäfer M; Schmeiser T; Strangfeld A; Schulze-Koops H; Voll RE; Specker C; Regierer AC
RMD Open; 2021 Jan; 7(1):. PubMed ID: 33479021
[TBL] [Abstract][Full Text] [Related]
19. Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial.
Li JX; Hou LH; Gou JB; Yin ZD; Wu SP; Wang FZ; Zhang Z; Peng ZH; Zhu T; Shen HB; Chen W; Zhu FC;
Lancet Infect Dis; 2023 Oct; 23(10):1143-1152. PubMed ID: 37352880
[TBL] [Abstract][Full Text] [Related]
20. Safety of COVID-19 Vaccination in Patients With Breast Cancer: Cross-Sectional Study in China.
Zhang S; Li J; Xu R; Chen Q; Sun G; Lin Y; Cao Y; Chen Y; Geng C; Teng Y; Nie J; Li X; Xu G; Liu X; Jin F; Fan Z; Luo T; Liu H; Wang FS; Jiang Z
JMIR Public Health Surveill; 2023 Dec; 9():e46009. PubMed ID: 38060302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
